Lexicon Pharmaceuticals
LXRX
121 hedge funds and large institutions have $1.29B invested in Lexicon Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 45 increasing their positions, 37 reducing their positions, and 15 closing their positions.
86% more call options, than puts
Call options by funds: $4.86M | Put options by funds: $2.62M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
37% more capital invested
Capital invested by funds: $940M → $1.29B (+$351M)
22% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 37
1.11% less ownership
Funds ownership: 103.95% → 102.84% (-1.1%)
4% less funds holding
Funds holding: 126 → 121 (-5)
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
Top Buyers
| 1 |
AG
Artal Group
Luxembourg
|
+$20.1M |
| 2 |
Millennium Management
New York
|
+$4.39M |
| 3 |
BlackRock
New York
|
+$2M |
| 4 |
PCM
Price Capital Management
Lafayette,
Louisiana
|
+$1.38M |
| 5 |
CLM
ClearBridge LLC (Maryland)
Baltimore,
Maryland
|
+$1.31M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Squarepoint
New York
| – | -$171K | -19,928 | Closed |
|
127
Teacher Retirement System of Texas
Austin,
Texas
| – | -$90K | -10,479 | Closed |
|
128
First Manhattan
New York
| – | -$42K | -5,000 | Closed |
|
|
PWM
129
Perigon Wealth Management
San Francisco,
California
| – | -$30K | -3,489 | Closed |
|
|
FCAG
130
First Capital Advisors Group
Little Silver,
New Jersey
| – | -$11K | -1,254 | Closed |
|
|
LWM
131
Lenox Wealth Management
Cincinnati,
Ohio
| – | -$8K | -1,035 | Closed |
|
|
KF
132
Krilogy Financial
St. Louis,
Missouri
| – | -$4K | -500 | Closed |
|
|
IA
133
IFP Advisors
Tampa,
Florida
| – | -$3K | -300 | Closed |
|
|
IWM
134
IHT Wealth Management
Chicago,
Illinois
| – | -$1K | -73 | Closed |
|
|
PHK
135
Point72 Hong Kong
Hong Kong
| – | -$1K | -71 | Closed |
|
LXRX Hedge Fund Activity: Q2 2018 in Review
121 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q2 2018, worth a combined $1.29B — up 37% from $940M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of LXRX and 11 opened new positions — a net loss of 4 holders — while 37 trimmed existing stakes and 45 added.
The largest buyer was Artal Group, adding an estimated $20.1M. The largest seller was USS Investment Management, exiting entirely with an estimated $22.6M sold.
- 121 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q2 2018, down from 126 in Q1 2018.
- Funds reported $1.29B of Lexicon Pharmaceuticals stock for Q2 2018, up 37% quarter-over-quarter.
- 11 funds opened new Lexicon Pharmaceuticals positions in Q2 2018 and 15 closed out, a net change of -4 holders.
- The largest Lexicon Pharmaceuticals buyer in Q2 2018 was Artal Group, an estimated $20.1M added.
- The largest Lexicon Pharmaceuticals seller in Q2 2018 was USS Investment Management, an estimated $22.6M sold.
Based on aggregated 13F filings for Q2 2018.